Becton Dickinson Reports Positive Study Results for Device to Treat Iliac Artery Disease
Dow Jones
Yesterday
Becton Dickinson said a device aimed at treating iliac artery disease met the primary composite endpoint in a recent trial.
The medical-device maker said Wednesday that treatment with its Revello Vascular Covered Stent at nine months met a composite safety and effectiveness endpoint with a failure rate of 2.8%, below the 19% goal set ahead of time.
Patients experienced gains in daily function and mobility, the company said.
The company said the results support the continued evaluation of the device. Clinical follow-up for the study's iliac cohort is ongoing through 36 months, the company said.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.